SG11201408254UA - N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products - Google Patents
N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal productsInfo
- Publication number
- SG11201408254UA SG11201408254UA SG11201408254UA SG11201408254UA SG11201408254UA SG 11201408254U A SG11201408254U A SG 11201408254UA SG 11201408254U A SG11201408254U A SG 11201408254UA SG 11201408254U A SG11201408254U A SG 11201408254UA SG 11201408254U A SG11201408254U A SG 11201408254UA
- Authority
- SG
- Singapore
- Prior art keywords
- berlin
- international
- str
- arylcarboxamides
- quinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12004764 | 2012-06-26 | ||
| PCT/EP2013/063118 WO2014001247A1 (en) | 2012-06-26 | 2013-06-24 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408254UA true SG11201408254UA (en) | 2015-01-29 |
Family
ID=48699019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408254UA SG11201408254UA (en) | 2012-06-26 | 2013-06-24 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
Country Status (41)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106413715A (zh) * | 2014-04-22 | 2017-02-15 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| EP3452029A4 (en) * | 2016-05-04 | 2019-10-30 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| US11066383B2 (en) | 2016-05-04 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328821A (en) | 1991-12-12 | 1994-07-12 | Robyn Fisher | Cold and cryo-preservation methods for human tissue slices |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| EP1296953A2 (en) | 2000-06-23 | 2003-04-02 | Eli Lilly And Company | Methods and compounds for inhibiting mrp1 |
| JP4342935B2 (ja) | 2001-06-22 | 2009-10-14 | 協和発酵キリン株式会社 | 肝細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| AU2003261974A1 (en) | 2002-09-11 | 2004-04-30 | Kureha Chemical Industry Company, Limited | Amine compounds and use thereof |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| DE602004022633D1 (de) | 2003-01-30 | 2009-10-01 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
| SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| WO2005094251A2 (en) | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3muscarinic acetylcholine receptor antagonists |
| SE0401342D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| WO2005117570A1 (en) | 2004-05-27 | 2005-12-15 | Jack Saffron | Feeding dish to prevent pest infestation |
| JP2008519761A (ja) | 2004-11-09 | 2008-06-12 | スミスクライン ビーチャム コーポレーション | グリコーゲンホスホリラーゼ阻害化合物およびその医薬組成物 |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| US20060293341A1 (en) | 2005-06-23 | 2006-12-28 | Vrej Jubian | Alkyl sulfonamide derivatives |
| WO2007091694A1 (en) | 2006-02-06 | 2007-08-16 | Showa Denko K.K. | Whitening dermatological preparations |
| CA2655128A1 (en) | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2008064432A1 (en) | 2006-12-01 | 2008-06-05 | The University Of Sydney | Polycyclic molecular compounds |
| JP5634263B2 (ja) | 2007-08-16 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナゾリンジオンキマーゼ阻害剤 |
| CA2966280A1 (en) | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
| MX2010012290A (es) | 2008-05-14 | 2011-02-21 | Amgen Inc | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. |
| US20110229469A1 (en) | 2008-10-01 | 2011-09-22 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| KR20120051022A (ko) | 2009-07-21 | 2012-05-21 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리데 바이러스의억제제 |
| WO2011029782A1 (en) | 2009-09-11 | 2011-03-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
-
2013
- 2013-06-24 HU HUE13731325A patent/HUE032306T2/en unknown
- 2013-06-24 ME MEP-2016-292A patent/ME02590B/me unknown
- 2013-06-24 PE PE2014002495A patent/PE20150154A1/es active IP Right Grant
- 2013-06-24 WO PCT/EP2013/063118 patent/WO2014001247A1/en active Application Filing
- 2013-06-24 UA UAA201500561A patent/UA115447C2/uk unknown
- 2013-06-24 CA CA2877786A patent/CA2877786C/en not_active Expired - Fee Related
- 2013-06-24 AP AP2014008141A patent/AP3919A/en active
- 2013-06-24 US US14/408,876 patent/US9428460B2/en active Active
- 2013-06-24 PL PL13731325T patent/PL2864291T3/pl unknown
- 2013-06-24 LT LTEP13731325.0T patent/LT2864291T/lt unknown
- 2013-06-24 JP JP2015519023A patent/JP6181172B2/ja not_active Expired - Fee Related
- 2013-06-24 EA EA201500039A patent/EA028063B1/ru not_active IP Right Cessation
- 2013-06-24 RS RS20161149A patent/RS55500B1/sr unknown
- 2013-06-24 BR BR112014032538A patent/BR112014032538A2/pt not_active Application Discontinuation
- 2013-06-24 DK DK13731325.0T patent/DK2864291T3/en active
- 2013-06-24 ES ES13731325.0T patent/ES2609455T3/es active Active
- 2013-06-24 AU AU2013283543A patent/AU2013283543B2/en not_active Ceased
- 2013-06-24 NZ NZ703100A patent/NZ703100A/en not_active IP Right Cessation
- 2013-06-24 SI SI201330440A patent/SI2864291T1/sl unknown
- 2013-06-24 PT PT137313250T patent/PT2864291T/pt unknown
- 2013-06-24 SG SG11201408254UA patent/SG11201408254UA/en unknown
- 2013-06-24 MA MA37700A patent/MA37700B1/fr unknown
- 2013-06-24 MX MX2014016054A patent/MX2014016054A/es unknown
- 2013-06-24 EP EP13731325.0A patent/EP2864291B1/en active Active
- 2013-06-24 JO JOP/2013/0192A patent/JO3342B1/ar active
- 2013-06-24 KR KR20157001996A patent/KR20150023880A/ko not_active Application Discontinuation
- 2013-06-26 AR ARP130102253 patent/AR091565A1/es unknown
- 2013-06-26 UY UY0001034881A patent/UY34881A/es not_active Application Discontinuation
- 2013-06-26 TW TW102122775A patent/TWI600646B/zh not_active IP Right Cessation
-
2014
- 2014-12-09 IL IL236146A patent/IL236146B/en active IP Right Grant
- 2014-12-18 CR CR20140593A patent/CR20140593A/es unknown
- 2014-12-18 CL CL2014003443A patent/CL2014003443A1/es unknown
- 2014-12-18 CU CUP2014000144A patent/CU20140144A7/es unknown
- 2014-12-19 EC ECIEPI201432516A patent/ECSP14032516A/es unknown
- 2014-12-19 CO CO14279115A patent/CO7170167A2/es unknown
- 2014-12-19 DO DO2014000295A patent/DOP2014000295A/es unknown
- 2014-12-22 PH PH12014502869A patent/PH12014502869B1/en unknown
- 2014-12-25 TN TN2014000532A patent/TN2014000532A1/fr unknown
-
2015
- 2015-07-21 HK HK15106940.1A patent/HK1206346A1/xx not_active IP Right Cessation
-
2016
- 2016-12-19 HR HRP20161745TT patent/HRP20161745T1/hr unknown
- 2016-12-23 CY CY20161101343T patent/CY1118412T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807426WA (en) | Immunomodulators | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201803882PA (en) | Oat-based product and process of manufacture | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201408254UA (en) | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | |
| SG11201408502XA (en) | Method of purifying an antibody |